ARCUTIS BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $17.95 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $18.58, a 91.55% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $9.70, a 257.93% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $2.71, a 75.21% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $10.93, a 15.53% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $9.94, a 168.65% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $3.70, a 53.81% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $8.01, a 43.11% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $14.08, a 26.70% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.95 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $18.58 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $9.94 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $9.69 10-Q · filed 2025-10-28 | |||
| 2025-06-30 | $9.69 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $9.70 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $3.70 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $3.64 10-Q · filed 2025-10-28 | |||
| 2024-06-30 | $3.59 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $2.71 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $8.01 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $8.76 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $10.25 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | $10.93 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $14.08 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $14.13 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $13.41 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $12.94 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $19.21 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $19.48 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $21.17 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $21.74 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $18.16 10-K · filed 2021-02-16 | |||
| 2020-09-30 | $18.35 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $18.71 10-Q · filed 2020-08-11 | |||
| 2020-03-31 | $16.94 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |